US fertility rates drop to record low in 2025 as births fall

The U.S. general fertility rate hit a record low in 2025, with provisional CDC data showing births fell as fewer women had children and many delayed starting families. The general fertility rate has declined nearly 23% since 2007, extending a nearly two-decade downward trend. The release is factual demographic data with potential long-term economic implications but is unlikely to move markets in the near term.

Analysis

Consumer-facing supply chains will see uneven stress: diversified staples/retailers will absorb lower newborn-driven SKU velocity with minimal top-line pain (single-digit bps on consolidated revenue), while pure-play infant brands, formula manufacturers and private-label suppliers face concentrated volume risk and margin pressure within 6–24 months as inventories reprice and promotions rise. Expect distributors and label contract manufacturers to see order smoothing that compresses seasonal peaks — that lowers working capital needs but forces factory idling decisions that disproportionally hurt smaller suppliers with >50% exposure to infant categories.

Healthcare is the asymmetric opportunity: clinical fertility services and high-end reproductive tech gain from higher per-patient yield (more cycles, higher use of adjunctive diagnostics) even if overall births compress. Uptake elasticity is sensitive to employer/payer coverage and out-of-pocket cost; a regulatory/payer expansion of fertility benefits is a plausible 6–24 month catalyst that could materially lift utilization and ARPU for fertility-benefit managers and clinic chains.

Macro/demand reversals are real risks — immigration policy, common-law changes around parental leave, or a cyclical uptick in household formation would blunt secular effects and are plausible within a 1–5 year horizon. For investors, the market likely misprices concentrated exposure: consumer staples headline risk is being conflated with durable structural winners in fertility tech and benefits management; hedge sizing and time-staggered entries around earnings and policy windows are critical to capture asymmetry while limiting drawdown from policy reversals.

Key Decisions for Investors

• Long COO (CooperCompanies) — 12–24 month core position (target 3–5% portfolio). Rationale: direct exposure to reproductive health devices and clinic supplies; buy shares or a 12–18 month call spread to limit capital. Risk/reward: modest downside if elective procedures dip in recession; 2:1 upside if clinic utilization and device attach-rates rise 15–25% over 12–24 months.
• Long PGNY (Progyny) — 9–18 month directional trade via long-dated calls (buy 12-month ATM calls, sell outsized OTM calls to finance). Rationale: benefits manager levered to increased IVF utilization and employer adoption; policy or large client wins can re-rate forward multiples. Risk/reward: regulatory or client-concierge churn is a 30–40% downside tail; reward is 100–150%+ if utilization accelerates and gross margin expands.
• Short BFAM (Bright Horizons) — 6–12 month tactical short or buy puts (size 1–2% net exposure). Rationale: enrollment and classroom demand contraction will pressure utilization and force promotional price moves; earnings guidance risk near-term. Risk/reward: downside capped by corporate contracts and diversified services; set stop if sequential enrollment stabilizes for two quarters.
• Pair trade — short KMB (Kimberly‑Clark) vs long COO/PGNY — 6–18 months. Rationale: hedge macro & staples noise while keeping directional exposure to fertility upside. Execution: size short to offset portfolio beta; target asymmetric payoff where staples re-rate modestly but fertility names re-rate materially on utilization/payer catalysts.